Is Peptigen a funded company?

Peptigen is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Peptigen rank among its competitors?

Peptigen ranks 41st amongst 39 active competitors, of which 3 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Conifer Point, which secured $2.64M in Jun, 2025.

Who are the top competitors of Peptigen?

Peptigen's top competitors include Aganitha, HQS Quantum Simulations and Cellumen. Among them, Conifer Point secured the most recent funding round in June, 2025.

Peptigen - 2026 Company Profile & Competitors

Peptigen is an unfunded company, founded in 2017. It operates as a Developer of AI platform for discovery and design of novel molecules. Peptigen has not raised any funding yet. The company has 39 active competitors, including 3 funded and 2 that have exited. Its top competitors include companies like Aganitha, HQS Quantum Simulations and Cellumen.

Company Details

Developer of AI platform for discovery and design of novel molecules. The company focuses on identifying and creating patentable, effective, and safe molecules with specific properties. It utilizes artificial intelligence and deep machine learning for molecule design across various sectors. The company offers services including peptide and small molecule design, synthesis, and activity research.

Key Metrics

Founded Year

2017

Stage

Unfunded

Ranked

41^st among 49 competitors

Similar Companies

Aganitha & 47 more

View Peptigen's full profile

Peptigen has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Peptigen include Aganitha, HQS Quantum Simulations and Cellumen. Here is the list of Top 10 competitors of Peptigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aganitha 2017, Hyderabad (India), Funding Raised	Provider of AI-powered drug discovery and development solutions	-	Technextchallenge & 1 others	44/100
2nd	HQS Quantum Simulations 2017, Karlsruhe (Germany), Series A	Developer of quantum simulation software for spectroscopy and related techniques	$16.2M	b2venture, HTGF & 10 others	43/100
3rd	Cellumen 2004, Pittsburgh (United States), Acquired	Biomarkers, antibodies, assay kits, and reagents for life science research	$12.2M	Novitas Capital, Innovation Works & 2 others	35/100
4th	PointCross 2000, Foster City (United States), Seed	Life science software solutions for clinical data automation and regulatory submissions	$120K	-	33/100
5th	ConcR 2018, London (United Kingdom), Seed	Provider of a platform predicting therapeutic response and outcome for cancer	$3.07M	Avonmore Developments, Cambridge Angels & 6 others	31/100
6th	Novomol 2017, Lorrach (Germany), Unfunded	Computational drug discovery services	-	-	29/100
7th	Kinentia Biosciences 2007, Albany (United States), Unfunded	Drug discovery and development services, chemoinformatics, and chemical catalog provider	-	-	28/100
8th	Conifer Point 2015, Doylestown (United States), Acquired	Developer of new drugs using custom fragment-based drug design software	-	HHS	25/100
9th	Emergentec 2002, Vienna (Austria), Funding Raised	Computational solutions and consulting for better decision making in biomarker, target and drug development.	-	Europa	24/100
10th	InSilicoMinds 2021, Hyderabad (India), Funding Raised	Provider of AI and advanced modeling and simulation solutions	-	Unusual Innovation	24/100
41st	Peptigen 2017, Unfunded	Developer of AI platform for discovery and design of novel molecules	-	-	16/100